Akorn announced that its manufacturing and development partner, Sofgen Pharmaceuticals, has received approval of its abbreviated new drug application (ANDA) for Progesterone Capsules, the generic of Abbott Laboratories‘ Prometrium (micronized progesterone).
Prometrium is indicated to prevent endometrial hyperplasia in postmenopausal women with an intact uterus receiving conjugated estrogens. It is also indicated for secondary amenorrhea.
Akorn has begun distribution of Progesterone Capsules, which are available in 100mg and 200mg dosage strengths.
For more information call (800) 932-5676 or visit www.akorn.com.